LOTUSENZA^®
(letrozole)
LOTUS
HK Reg. No. HK68544 (16 Jan, 2025)  
Composition:¹

•    Yellow, circular, biconvex film-coated tablets, plain on both sides
•    Each tablet contains 2.5 mg letrozole

Indication:¹

•    Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer 
•    Extended adjuvant treatment of hormone-dependent early invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years
•    First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer
•    Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with antiestrogens
•    Neoadjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated

References
1. EMC. Letrozole 2.5 mg film-coated tablets SmPC.  30 December 2024. Available from: https://www.medicines.org.uk/emc/product/9957/smpc#gref. [Accessed 19 February 2025].  2. Sinovac. 23-Valent Pneumococcal Polysaccharide Vaccine. Available from: https://www.sinovac.com/zh-cn/portfolio/ppv23. [Accessed 20 February 2025].  3. FDA. IMDELLTRA® Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf. [Accessed 20 February 2025].  4. EMC. Atracurium besilate SmPC. 2 November 2023. Available from: https://www.medicines.org.uk/emc/product/951/smpc#gref. [Accessed 20 February 2025].